Protagenic Therapeutics, Inc.\new Share-based Payment Arrangement, Expense
Protagenic Therapeutics, Inc.\new (PTIX) reported Share-based Payment Arrangement, Expense of $67.01 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-19
- Protagenic Therapeutics, Inc.\new share-based payment arrangement, expense for the quarter ending 2026-06-30 was $67.01K, a 46.44% decline year-over-year.
- Protagenic Therapeutics, Inc.\new share-based payment arrangement, expense for the quarter ending 2025-06-30 was $125.13K.
- Protagenic Therapeutics, Inc.\new share-based payment arrangement, expense for fiscal 2026 was $418.59K.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|
| 2026-06-30 | $67.01K 10-Q · filed 2026-08-19 | ||
| 2026-03-31 | $418.59K 10-K · filed 2026-08-14 | ||
| 2025-06-30 | $125.13K 10-Q · filed 2026-08-19 | ||
| 2019-09-30 | $850.77K 10-Q · filed 2019-11-14 | ||
| 2018-09-30 | $868.93K 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |